Investor updates Keyword Search Clear 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with ... more Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult ... more Published on: 12 December 2011 First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer Separate study indicates that GA101 is highly effective in combination with chemotherapy. Roche announced today that its investigational unique type II anti-CD20 antibody GA101 (obinutuzumab) ... more Published on: 8 December 2011 Reminder: Roche conference call for investors and analysts from SABCS 2011 CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, ... more Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, ... more Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for ... more Published on: 30 November 2011 Roche conference call for investors and analysts from SABCS 2011 CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, ... more Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer ... more Published on: 23 November 2011 Roche purchases shares in tender offer for Anadys Pharmaceuticals Roche today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of ... more Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of ... more Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell ... more Published on: 31 October 2011 Reminder: Invitation to Late-stage pipeline event The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. more Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple ... more Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a ... more Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 ... more Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 ... more Published on: 11 October 2011 Invitation to Late-stage pipeline event Monday, 7 November 2011 The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. The event will provide an ... more Published on: 6 October 2011 Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. more Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus ... more Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. more Published on: 26 September 2011 Peginterferon alfa-2a “Pegasys®” Approved for Additional Indication of “Chronic Active Hepatitis B” Please find attached a press release by Chugai more Published on: 26 September 2011 Anti-Cancer Agent, Avastin® Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“ Please find attached a press release by Chugai. more Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). more Published on: 24 September 2011 Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing Roche today announced that AVAPERL, a phase III study evaluating the combination of Avastin® (bevacizumab) and chemotherapy for patients with previously untreated, advanced non-squamous non-small ... more Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and ... more Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 ... more Published on: 14 September 2011 Invitation to Roche's Third Quarter Sales 2011 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. more Published on: 13 September 2011 Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. more Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones ... more Published on: 2 September 2011 Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] announced today that it has entered into license agreements with F. Hoffmann-La Roche, ... more Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved ... more Published on: 29 August 2011 Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease Roche announced today results from two exploratory mechanistic Phase IIb studies investigating dalcetrapib’s effects on atherosclerotic disease progression (dal-PLAQUE) and vascular function ... more Published on: 25 August 2011 Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE We kindly invite investors and analysts to participate in a conference call that will be held during the European Society of Cardiology Congress taking place from 27-31 August 2011 in Paris. more Published on: 22 August 2011 Investor Day: Roche Diagnostics Enabling Personalised Healthcare We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. more Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as ... more Published on: 15 August 2011 Roche Investor Science Event from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE - Monday, 29 August 2011, Paris, France more Published on: 15 August 2011 Chugai to In-license BRAF Inhibitor Vemurafenib Dear Investor, Please find attached a press release by Chugai. more Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. ... more Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the ... more Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a ... more Published on: 22 July 2011 Full reconciliation of Chugai interim results into IFRS Results of Chugai as consolidated by the Roche Group. Following the publication of Chugai’s official 2011 interim results, Roche offers this investor update which reconciles these results with the ... more Published on: 21 July 2011 Roche on track – full year earnings outlook increased Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. more Published on: 19 July 2011 Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. more Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. more Published on: 14 July 2011 Reminder: Invitation to Roche's Half Year Results for 2011 Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). more Published on: 14 July 2011 Roche researchers develop antibody that crosses the blood-brain barrier more efficiently Roche announced today two research publications from its Early Development unit gRED outlining how a new technology successfully facilitated transport of an anti-amyloidogenic antibody across the ... more Published on: 1 July 2011 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more Published on: 1 July 2011 Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of “Pancreatic Cancer Not Amenable to Curative Resection“ and Measures for Proper Use Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast ... more Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory ... more Published on: 29 June 2011 Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy Two-Year Data from RISE and RIDE studies presented at the American Diabetes Association Annual Scientific Sessions. Genentech, a member of the Roche Group, today announced 24-month results from the ... more Published on: 24 June 2011 Invitation to Roche's Half Year Results for 2011 Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). more Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. more Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase ... more Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin ... more Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC ... more Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers ... more Published on: 27 May 2011 Roche Analyst Event at ASCO 2011 Analyst briefing on data presented at ASCO: Sunday, 5th June 2011. We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at ... more Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League ... more Published on: 20 May 2011 RoActemra offers a new option for children living with a rare and severe form of arthritis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the RoActemra (tocilizumab) rheumatoid arthritis label in ... more Published on: 20 May 2011 Roche ASCO Planner Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3 - 7, 2011. In ... more Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer more Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented more Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness ... more Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to ... more Published on: 5 May 2011 Roche Analyst Event at ASCO 2011 Analyst briefing on data presented at ASCO: Sunday, 5 June 2011 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at ... more Published on: 26 April 2011 Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe,” approved in Japan Press release by Chugai more Published on: 20 April 2011 FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis Roche and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab), in combination with corticosteroids, as a new medicine for adults with ... more Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This ... more Published on: 19 April 2011 Diversity of approaches in research continues to empower scientific excellence at Roche Roche announced today that the Group's strong scientific publication track record from Genentech's and Roche's Research and Early Development units gRED and pRED continues. more Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for ... more Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients more Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss ... more Published on: 7 April 2011 Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT ... more Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared ... more Published on: 1 April 2011 Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results Roche announced today that the results from two exploratory Phase IIb studies, dal-VESSEL and dal-PLAQUE, further support the promising safety profile of dalcetrapib, its first-in-class cholesteryl ... more Published on: 28 March 2011 Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME) Results consistent with data released last month showing patients with DME who received Lucentis achieved significant improvement in vision. Roche announced today that the second of two Phase III ... more Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal ... more Published on: 15 March 2011 Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT ... more Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in ... more Published on: 10 March 2011 Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema Roche today announced that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema (DME) who received Lucentis (ranibizumab injection) experienced rapid and ... more Published on: 10 March 2011 Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection more Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. more Published on: 1 March 2011 Roche Annual General Meeting: dividend raised by 10% Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total ... more Published on: 25 February 2011 Pivotal Study Validates Roche’s cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the ... more Published on: 23 February 2011 Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection Dear Investor, Please find attached a press release by Chugai: http://www.roche.com/inv-update-2011-02-23-annex.pdf Do not hesitate to contact us for any further questions. more Published on: 16 February 2011 Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma Roche today announced the initiation of a phase III study to investigate a subcutaneous formulation of MabThera (rituximab) for patients with CD20+ non-Hodgkin’s lymphoma (NHL). more Published on: 14 February 2011 Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME) Roche today announced that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious ... more Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until ... more Published on: 2 February 2011 Full reconciliation of Chugai 2010 results into IFRS Following the publication of Chugai's official 2010 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche ... more Published on: 2 February 2011 Solid overall results Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities more Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to ... more Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim ... more Published on: 19 January 2011 Reminder: Invitation to Roche's Full Year Results for 2010 Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. more Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 ... more Published on: 17 January 2011 Changes to the Roche Corporate Executive Committee Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans ... more Published on: 5 January 2011 FDA grants supplemental approval for ACTEMRA Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical ... more Published on: 4 January 2011 Roche's Full Year Results for 2010 Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides ... more
Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with ... more
Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult ... more
Published on: 12 December 2011 First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer Separate study indicates that GA101 is highly effective in combination with chemotherapy. Roche announced today that its investigational unique type II anti-CD20 antibody GA101 (obinutuzumab) ... more
Published on: 8 December 2011 Reminder: Roche conference call for investors and analysts from SABCS 2011 CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, ... more
Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, ... more
Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for ... more
Published on: 30 November 2011 Roche conference call for investors and analysts from SABCS 2011 CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive metastatic breast cancer. Friday, 9 December 2011, San Antonio TX, ... more
Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer ... more
Published on: 23 November 2011 Roche purchases shares in tender offer for Anadys Pharmaceuticals Roche today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of ... more
Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of ... more
Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell ... more
Published on: 31 October 2011 Reminder: Invitation to Late-stage pipeline event The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. more
Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple ... more
Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a ... more
Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 ... more
Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 ... more
Published on: 11 October 2011 Invitation to Late-stage pipeline event Monday, 7 November 2011 The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time. The event will provide an ... more
Published on: 6 October 2011 Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. more
Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus ... more
Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. more
Published on: 26 September 2011 Peginterferon alfa-2a “Pegasys®” Approved for Additional Indication of “Chronic Active Hepatitis B” Please find attached a press release by Chugai more
Published on: 26 September 2011 Anti-Cancer Agent, Avastin® Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“ Please find attached a press release by Chugai. more
Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). more
Published on: 24 September 2011 Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing Roche today announced that AVAPERL, a phase III study evaluating the combination of Avastin® (bevacizumab) and chemotherapy for patients with previously untreated, advanced non-squamous non-small ... more
Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and ... more
Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 ... more
Published on: 14 September 2011 Invitation to Roche's Third Quarter Sales 2011 Conference Call Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday 13th October, 2011. more
Published on: 13 September 2011 Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. more
Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones ... more
Published on: 2 September 2011 Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] announced today that it has entered into license agreements with F. Hoffmann-La Roche, ... more
Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved ... more
Published on: 29 August 2011 Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease Roche announced today results from two exploratory mechanistic Phase IIb studies investigating dalcetrapib’s effects on atherosclerotic disease progression (dal-PLAQUE) and vascular function ... more
Published on: 25 August 2011 Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE We kindly invite investors and analysts to participate in a conference call that will be held during the European Society of Cardiology Congress taking place from 27-31 August 2011 in Paris. more
Published on: 22 August 2011 Investor Day: Roche Diagnostics Enabling Personalised Healthcare We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT at the London Stock Exchange. more
Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as ... more
Published on: 15 August 2011 Roche Investor Science Event from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE - Monday, 29 August 2011, Paris, France more
Published on: 15 August 2011 Chugai to In-license BRAF Inhibitor Vemurafenib Dear Investor, Please find attached a press release by Chugai. more
Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. ... more
Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the ... more
Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a ... more
Published on: 22 July 2011 Full reconciliation of Chugai interim results into IFRS Results of Chugai as consolidated by the Roche Group. Following the publication of Chugai’s official 2011 interim results, Roche offers this investor update which reconciles these results with the ... more
Published on: 21 July 2011 Roche on track – full year earnings outlook increased Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. more
Published on: 19 July 2011 Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more
Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. more
Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. more
Published on: 14 July 2011 Reminder: Invitation to Roche's Half Year Results for 2011 Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). more
Published on: 14 July 2011 Roche researchers develop antibody that crosses the blood-brain barrier more efficiently Roche announced today two research publications from its Early Development unit gRED outlining how a new technology successfully facilitated transport of an anti-amyloidogenic antibody across the ... more
Published on: 1 July 2011 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more
Published on: 1 July 2011 Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of “Pancreatic Cancer Not Amenable to Curative Resection“ and Measures for Proper Use Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more
Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast ... more
Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory ... more
Published on: 29 June 2011 Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy Two-Year Data from RISE and RIDE studies presented at the American Diabetes Association Annual Scientific Sessions. Genentech, a member of the Roche Group, today announced 24-month results from the ... more
Published on: 24 June 2011 Invitation to Roche's Half Year Results for 2011 Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET / 6:00 BST / 1:00 AM EDT / 10:00 PM PDT (evening before). more
Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. more
Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase ... more
Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin ... more
Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC ... more
Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers ... more
Published on: 27 May 2011 Roche Analyst Event at ASCO 2011 Analyst briefing on data presented at ASCO: Sunday, 5th June 2011. We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at ... more
Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League ... more
Published on: 20 May 2011 RoActemra offers a new option for children living with a rare and severe form of arthritis Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an extension to the RoActemra (tocilizumab) rheumatoid arthritis label in ... more
Published on: 20 May 2011 Roche ASCO Planner Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3 - 7, 2011. In ... more
Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer more
Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented more
Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness ... more
Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to ... more
Published on: 5 May 2011 Roche Analyst Event at ASCO 2011 Analyst briefing on data presented at ASCO: Sunday, 5 June 2011 We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at ... more
Published on: 26 April 2011 Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe,” approved in Japan Press release by Chugai more
Published on: 20 April 2011 FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis Roche and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab), in combination with corticosteroids, as a new medicine for adults with ... more
Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This ... more
Published on: 19 April 2011 Diversity of approaches in research continues to empower scientific excellence at Roche Roche announced today that the Group's strong scientific publication track record from Genentech's and Roche's Research and Early Development units gRED and pRED continues. more
Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for ... more
Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients more
Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss ... more
Published on: 7 April 2011 Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT ... more
Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared ... more
Published on: 1 April 2011 Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results Roche announced today that the results from two exploratory Phase IIb studies, dal-VESSEL and dal-PLAQUE, further support the promising safety profile of dalcetrapib, its first-in-class cholesteryl ... more
Published on: 28 March 2011 Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME) Results consistent with data released last month showing patients with DME who received Lucentis achieved significant improvement in vision. Roche announced today that the second of two Phase III ... more
Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal ... more
Published on: 15 March 2011 Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday April 14th, 2011 07:00 CEST / 06:00 BST / 01:00 AM EDT / 22:00 PM PDT ... more
Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in ... more
Published on: 10 March 2011 Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema Roche today announced that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema (DME) who received Lucentis (ranibizumab injection) experienced rapid and ... more
Published on: 10 March 2011 Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection more
Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. more
Published on: 1 March 2011 Roche Annual General Meeting: dividend raised by 10% Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total ... more
Published on: 25 February 2011 Pivotal Study Validates Roche’s cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability of the cobas HPV Test to individually detect HPV-16 and HPV-18, two of the ... more
Published on: 23 February 2011 Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection Dear Investor, Please find attached a press release by Chugai: http://www.roche.com/inv-update-2011-02-23-annex.pdf Do not hesitate to contact us for any further questions. more
Published on: 16 February 2011 Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma Roche today announced the initiation of a phase III study to investigate a subcutaneous formulation of MabThera (rituximab) for patients with CD20+ non-Hodgkin’s lymphoma (NHL). more
Published on: 14 February 2011 Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME) Roche today announced that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious ... more
Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until ... more
Published on: 2 February 2011 Full reconciliation of Chugai 2010 results into IFRS Following the publication of Chugai's official 2010 results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche ... more
Published on: 2 February 2011 Solid overall results Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities more
Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to ... more
Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim ... more
Published on: 19 January 2011 Reminder: Invitation to Roche's Full Year Results for 2010 Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. more
Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 ... more
Published on: 17 January 2011 Changes to the Roche Corporate Executive Committee Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans ... more
Published on: 5 January 2011 FDA grants supplemental approval for ACTEMRA Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical ... more
Published on: 4 January 2011 Roche's Full Year Results for 2010 Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides ... more